Clinical Trials Browser

Phase 1/2 × Interventional × spartalizumab × Clear all

NCT07353645 2026-04-15

KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT06425926 2026-03-27

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Phase 1/2 Recruiting

Melanoma

NCT05223231 2026-02-02

Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors

Phase 1/2 Completed

Advanced Malignant Tumors

NCT07365592 2026-01-26

Neo-CD

Phase 1/2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT02961101 2026-01-22

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Phase 1/2 Recruiting

Neoplasms, Recurrence

NCT05210413 2026-01-15

SPARTO

Phase 1/2 Active not recruiting

Other solid neoplasm

Refractory or Recurrent Solid Tumor

NCT06265727 2026-01-08

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor, Adult

NCT04146298 2025-12-24

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07245901 2025-11-24

Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Solid Tumor

NCT05941507 2025-09-24

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Phase 1/2 Recruiting

BreastCNSGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Glioblastoma, Head and Neck Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT04191421 2025-08-22

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

Phase 1/2 Completed

35 enrolled 10 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03104699 2025-07-30

A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

Phase 1/2 Completed

211 enrolled 29 charts

Uterine Cervical Neoplasms

NCT05978102 2025-07-23

A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT03815942 2025-06-25

ADVANCE

Phase 1/2 Terminated

23 enrolled 11 charts

Intermediate Risk Prostate Cancer

NCT06603844 2025-06-03

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT06802835 2025-05-16

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Phase 1/2 Recruiting

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT03958383 2025-04-18

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

Phase 1/2 Active not recruiting

Melanoma

NCT03058289 2025-02-27

IT-01

Phase 1/2 Completed

111 enrolled 21 charts

BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT05662397 2025-02-04

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

Phase 1/2 Active not recruiting

Neoplasms, Recurrence

NCT03009058 2024-11-25

MODULATE

Phase 1/2 Terminated

2 enrolled 7 charts

DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Sarcoma

NCT02325739 2024-10-21

FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression

Phase 1/2 Completed

172 enrolled 33 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT04669899 2024-04-09

Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

Phase 1/2 Completed

Neoplasms

NCT03393858 2024-02-07

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

Phase 1/2 Terminated

Other solid neoplasmThoracic

Mesothelioma, Malignant, Neoplasms

NCT03757858 2024-02-07

Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases

Phase 1/2 Completed

Neoplasm Metastasis, Neoplasms, Pelvic Neoplasms

NCT02829723 2024-01-18

A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

Phase 1/2 Terminated

192 enrolled 77 charts

Glioblastoma

NCT02608268 2023-12-06

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Phase 1/2 Terminated

252 enrolled 67 charts

DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT04193293 2023-09-21

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

Phase 1/2 Terminated

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06022692 2023-09-05

HEAIS001

Phase 1/2 Completed

Gastrointestinal

Hyperthermia, Digestive System Neoplasms

NCT02658890 2023-08-28

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

Phase 1/2 Completed

627 enrolled 59 charts

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT02795429 2023-07-03

Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC

Phase 1/2 Completed

89 enrolled 37 charts

Gastrointestinal

Liver Neoplasms

NCT05699811 2023-04-28

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT04652440 2023-04-19

Ablation Combined With PD-1 in HCC: Phase II Study

Phase 1/2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT05204862 2023-04-03

Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT01714739 2023-02-02

A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

Phase 1/2 Completed

337 enrolled 42 charts

Neoplasms

NCT03609424 2023-01-03

PDR001 Plus Imatinib for Metastatic or Unresectable GIST

Phase 1/2 Completed

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT02404441 2022-08-03

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Phase 1/2 Completed

319 enrolled 41 charts

BreastDermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT02460224 2022-02-10

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Phase 1/2 Completed

490 enrolled 77 charts

DermatologicGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Melanoma, Mesothelioma

NCT02807844 2021-08-11

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Phase 1/2 Completed

141 enrolled 58 charts

BreastDermatologicGastrointestinalGynecologic

Melanoma, Pancreatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03989310 2020-12-23

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer

Phase 1/2 Unknown

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT03351231 2020-08-26

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

Phase 1/2 Terminated

7 enrolled 6 charts

Neoplasms

NCT04368273 2020-04-29

CCRT+PD-1

Phase 1/2 Unknown

Uterine Cervical Neoplasms

NCT02466568 2019-09-09

Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis

NCT04004234 2019-07-09

A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC

Phase 1/2 Unknown

Gastrointestinal

Biliary Tract Neoplasms, Neoplasm Metastasis